Microdeletion syndrome

Jennifer S. Wilkov Finalizes Lineup for the 2022 October Speak Up Women Conference

Retrieved on: 
Saturday, October 29, 2022
Make, Human voice, Harvard Business Review, The Women's Conference, Workplace, Diagnosis, CNBC, Forbes, Cure, Conference, Keynote, CEO, UN, Solution, Empowerment, Ministry of Education (Malaysia), Reflexive pronoun, Equity, Human, Courage, Panel discussion, Extraversion and introversion, Human spirit, Inclusion, United Nations, Importance, Disability, Author, Microdeletion syndrome, DEI, Diversity Woman, Home, NEW, Sexual assault, Friends, Mobile phone, Interior design, Entertainment, Nightclub, Pharmaceutical industry, Woman, Google, Diversity

NEW YORK, Oct. 29, 2022 /PRNewswire/ -- Jennifer S. Wilkov, multi #1 international best-selling award-winning author, founder, and CEO of Speak Up World LLC, (http://www.SpeakUpWomen.com), announces the agenda and lineup of speakers for the 2022 October Global Speak Up Women Conference virtually online on Saturday, October 29, 2022. Starting at 9 AM EST, participants from around the world will engage in virtual talks about the importance of speaking up in women's personal and professional relationships and for causes she cares about to create change where change is necessary.

Key Points: 
  • "Speak Up Women is the #1 resource for women who want to speak up in their lives for the lives they imagine.
  • "It is a privilege to host these amazing women who will be speaking up during the October 2022 Speak Up Women Conference on Saturday," says Wilkov.
  • To register for the Speak Up Women Conference on Saturday, October 29, 2022, go to https://www.SpeakUpWomen.com .
  • The Speak Up Women Conference is a one-day immersive offered twice a year in the spring and fall.

Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy

Retrieved on: 
Thursday, October 27, 2022
JAMA Neurology, Life expectancy, Union, Muscular dystrophy, PIM, European Medicines Agency, UK, Vamorolone, NINDS, FDA, Dissociative, Ventilation, National Institutes of Health, MAA, Foundation, JAMA Network Open, Inflammation, CEO, Vitamin D deficiency, Food, Patient, Maintenance, Life Science Alliance, Cardiomyopathy, NDA, Heart, Orphan drug, Duchenne muscular dystrophy, Defense, EMA, NIAMS, Company, Weakness, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Doctor of Philosophy, Safety, Disease, LHON, DMD, National, European Commission, Leber's hereditary optic neuropathy, Adolescence, NCATS, Fibrosis, Microdeletion syndrome, Prednisone, Cystic fibrosis, Vomiting, Caregiver, Time, Pharmaceutical industry, Duchenne, MD

Completion of the vamorolone NDA submission is a major step towards our goal of bringing this investigational therapy to patients living with DMD, and represents a vital milestone for Santhera, said Dario Eklund, CEO of Santhera.

Key Points: 
  • Completion of the vamorolone NDA submission is a major step towards our goal of bringing this investigational therapy to patients living with DMD, and represents a vital milestone for Santhera, said Dario Eklund, CEO of Santhera.
  • With the completion of the rolling NDA submission, Santhera and ReveraGen have also applied for priority review.
  • ReveraGen was founded in 2008 to develop first-in-class dissociative steroidal drugs for Duchenne muscular dystrophy and other chronic inflammatory disorders.
  • The development of ReveraGens lead compound, vamorolone, has been supported through partnerships with foundations worldwide, including Muscular Dystrophy Association USA, Parent Project Muscular Dystrophy, Foundation to Eradicate Duchenne, Save Our Sons, JoiningJack, Action Duchenne, CureDuchenne, Ryans Quest, Alexs Wish, DuchenneUK, Pietros Fight, Michaels Cause, Duchenne Research Fund, and Defeat Duchenne Canada.

Geron to Announce Third Quarter 2022 Financial Results on November 3, 2022

Retrieved on: 
Thursday, October 27, 2022
Biotechnology, Pharmaceutical, Health, Company, Risk, Telephone, Nasdaq, Microdeletion syndrome, Corporation, Geron Corporation, Lymphatic system, Webcast, ID, Pharmaceutical industry

Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2022 financial results before the market opens on Thursday, November 3, 2022 via press release, which will be available on the Companys website at www.geron.com/investors .

Key Points: 
  • Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2022 financial results before the market opens on Thursday, November 3, 2022 via press release, which will be available on the Companys website at www.geron.com/investors .
  • Geron will host a conference call to discuss the financial results as well as key upcoming expected milestones at 9:00 a.m.
  • A live webcast of the conference call and related presentation will be available on the Companys website at www.geron.com/investors/events .
  • Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies.

FibroGen to Report Third Quarter 2022 Financial Results

Retrieved on: 
Monday, October 24, 2022
SAN, Pancreatic cancer, Interest, Therapy, Webcast, Dialysis, CTGF, IPF, HIF, NASDAQ, Microdeletion syndrome, MDS, Biology, Patient, Research, Duchenne, DMD, Duchenne muscular dystrophy, Anemia, Company, Idiopathic pulmonary fibrosis, GLOBE, CKD, LAPC, CIA, Pharmaceutical industry, Roxadustat

SAN FRANCISCO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2022 financial results on Monday, November 7 after the market close.

Key Points: 
  • SAN FRANCISCO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2022 financial results on Monday, November 7 after the market close.
  • FibroGen will also conduct a conference call on that day at 5:00 p.m.
  • ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.
  • FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology and autoimmune space.

EQS-News: Apogenix’ Asunercept Demonstrates Efficacy in Phase II Trial for the Treatment of Hospitalized COVID-19 Patients

Retrieved on: 
Saturday, October 22, 2022
Degenerative disease, European Medicines Agency, Immunoglobulin G, Medical University of Vienna, Disease, TRAIL, SOC, AbbVie, PRIME, Critical Care Medicine (journal), Priority, Medical school, Microdeletion syndrome, MDS, Patient, Data monitoring committee, Acute respiratory distress syndrome, DSMB, Standard of care, Federation, Lymphocytopenia, Mortality, II, Cancer, University, CD95, University of Cologne, WHO, TNF, III, Trial of the century, MD, Doctor of Philosophy, COVID-19, FC, Immunotherapy, Safety, GITR, Lymphatic system, Glioblastoma, Death, Pulmonology, Oxygen, CD40, Pharmaceutical industry, Asunercept, EU

Heidelberg, Germany, October 19, 2022 Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that asunercept showed statistically significant benefits for hospitalized COVID-19 patients in the ASUNCTIS trial.

Key Points: 
  • Heidelberg, Germany, October 19, 2022 Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that asunercept showed statistically significant benefits for hospitalized COVID-19 patients in the ASUNCTIS trial.
  • The open-label multi-center phase II trial investigated efficacy and safety of asunercept in 435 patients with moderate to severe COVID-19 disease.
  • COVID-19 patients were randomized equally into four study arms, receiving 25, 100, or 400mg asunercept (once weekly, i.v.)
  • The results show strong trends for clinical efficacy in all treatment groups, indicating a robust activity of asunercept.

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, October 20, 2022
Biotechnology, Pharmaceutical, Health, Microdeletion syndrome, Nasdaq, Company, Lymphatic system, Risk, Achievement, Geron Corporation, Employment, Corporation, Health insurance

Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 843,260 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Key Points: 
  • Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 843,260 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
  • The stock options were granted on October 19, 2022 at an exercise price of $2.25 per share, which is equal to the closing price of Geron common stock on the date of grant.
  • All of the stock options were granted as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the stock option agreements covering the grants and Gerons 2018 Inducement Award Plan, which was adopted December 14, 2018 and provides for the granting of stock options to new employees.
  • Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies.

Cornerstone Expands Content Portfolio with Technologies That Connect, Curate, and Manage Content from Anywhere

Retrieved on: 
Wednesday, October 19, 2022
Technology, Human Resources, Professional Services, Software, DEI (Diversity, Equity and Inclusion), Continuing, Training, Education, Artificial Intelligence, Adoption, SumTotal Systems, Universal Content Productions, Growth, Altacast, Organization, Diversity, Antisemitism, Content, Masters of Scale, Investment, Partnership, Microdeletion syndrome, Addiction, Learning, AI, Workplace, Inclusion, Phrase, Environment, Creativity, Heel, CCA, IMC Content Studio, Problem solving, Empathy, The Starters, Solution, Video game, Tutoring, Management

Cornerstone OnDemand, Inc. , a leader in talent experience solutions, today announced it has expanded its content portfolio by adding innovative technologies designed to collapse boundaries between content producers and learners, content and skill building.

Key Points: 
  • Cornerstone OnDemand, Inc. , a leader in talent experience solutions, today announced it has expanded its content portfolio by adding innovative technologies designed to collapse boundaries between content producers and learners, content and skill building.
  • Cornerstone Content Anytime, Anywhere Cornerstone is excited to bring its industry-leading Content Anytime (CCA) to every, and any, learning platform.
  • The company is also launching fresh Cornerstone Originals content available through Content Anytime subscriptions.
  • In the first half of 2022, Cornerstone saw more than 1 billion minutes of learning content consumed a nearly 27% increase from 2021, with 52 million minutes of learning content consumed via Cornerstone Content Anytime (CCA).

Karyopharm to Report Third Quarter 2022 Financial Results on November 3, 2022

Retrieved on: 
Thursday, October 20, 2022
LinkedIn, Therapy, Conference, Science, Multiple myeloma, Microdeletion syndrome, Twitter, Ruxolitinib, Multimedia, KPTI, Nasdaq, Endometrial cancer, Company, Industry, SINE, XPO1, View, Pharmaceutical industry

NEWTON, Mass., Oct. 20, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report third quarter 2022 financial results on Thursday, November 3, 2022. Karyopharm's management team will host a conference call and audio webcast at 4:30 p.m. ET on Thursday, November 3, 2022, to discuss the financial results and other company updates.

Key Points: 
  • ET --
    NEWTON, Mass., Oct.20, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report third quarter 2022 financial results on Thursday, November 3, 2022.
  • ET on Thursday, November 3, 2022, to discuss the financial results and other company updates.
  • For more information about our people, science and pipeline, please visit www.karyopharm.com , and follow us on Twitter at @Karyopharm and LinkedIn.
  • XPOVIOand NEXPOVIOare registered trademarks of Karyopharm Therapeutics Inc.
    View original content to download multimedia: https://www.prnewswire.com/news-releases/karyopharm-to-report-third-quar...

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit

Retrieved on: 
Monday, October 17, 2022
Joint Medical Service (Germany), D.C, European Medicines Agency, U.S. Securities and Exchange Commission, Microdeletion syndrome, FXS, Autism, Growth, Royal commission, ASD, Clinician Administered PTSD Scale, Infection, Private Securities Litigation Reform Act, Degenerative disease, DiGeorge syndrome, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Depression, Twitter, Annual report, INSPIRE, Fragile X syndrome, Security (finance), National Organization for Rare Disorders, Nasdaq, Form 10-K, Food, Company, Marketing, Adolescence, NORD, Anxiety, Behavior, Clinical Global Impression, Skin, Fast Track, GLOBE, FDA, COVID-19, European Commission, Poster, Pharmaceutical industry, Cannabidiol, Jean-François Zygel

In addition, the majority of patients showed clinically meaningful improvements as demonstrated by the Clinical Global Impression Improvement (CGI-I).

Key Points: 
  • In addition, the majority of patients showed clinically meaningful improvements as demonstrated by the Clinical Global Impression Improvement (CGI-I).
  • Zygel was shown to be well tolerated, and the safety profile was consistent with previously released data from other Zygel clinical trials.
  • Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders.
  • Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release.

Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies

Retrieved on: 
Monday, October 17, 2022
Oncology, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, U.S. Securities and Exchange Commission, Protein engineering, Therapy, CRS, SEC, Medicine, Risk, Acute myeloid leukemia, AML, DART, CD3, Cytokine release syndrome, NASDAQ, Microdeletion syndrome, MDS, Biotechnology, Patient, Lymphatic system, Research, Twitter, Security (finance), Program, Bispecific monoclonal antibody, Multimedia, Investment, Partnership, Gilead Sciences, Senior, Cancer, Private Securities Litigation Reform Act, HIV, EPS, CD123, Exercise, MD, Doctor of Philosophy, Industry, Science, Blood, Lists of disasters, Toxicity, CEO, Macrogen, GILD, IPR, COVID-19, Half-life, Pharmaceutical industry

Gilead Sciences, Inc. (NASDAQ: GILD) and MacroGenics (NASDAQ: MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics DART platform, and two additional bispecific research programs.

Key Points: 
  • Gilead Sciences, Inc. (NASDAQ: GILD) and MacroGenics (NASDAQ: MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics DART platform, and two additional bispecific research programs.
  • View the full release here: https://www.businesswire.com/news/home/20221016005052/en/
    A leader in the bispecific antibody space, MacroGenics has extensive experience applying its proprietary DART platform to develop novel therapeutics.
  • MacroGenics bispecific expertise naturally complements Gileads portfolio strengths in immuno-oncology and our growing hematology franchise, said Bill Grossman, MD, PhD, Senior Vice President, Oncology Clinical Development, Gilead Sciences.
  • Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.